Persistent Asset Partners Ltd Makes New Investment in Celcuity, Inc. $CELC

Persistent Asset Partners Ltd purchased a new position in Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 6,719 shares of the company’s stock, valued at approximately $670,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares in the last quarter. US Bancorp DE lifted its holdings in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Celcuity during the 4th quarter worth about $42,000. Finally, Ogorek Anthony Joseph NY ADV boosted its stake in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CELC. HC Wainwright cut their price objective on shares of Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a research note on Thursday, May 28th. Wells Fargo & Company cut their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Finally, Leerink Partners set a $155.00 price target on Celcuity in a research note on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.09.

Celcuity Trading Down 1.0%

Shares of CELC stock opened at $87.32 on Wednesday. The firm has a market cap of $4.26 billion, a P/E ratio of -22.39 and a beta of 0.10. Celcuity, Inc. has a 1-year low of $11.27 and a 1-year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The firm’s 50-day simple moving average is $118.82 and its 200-day simple moving average is $111.13.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. As a group, equities analysts forecast that Celcuity, Inc. will post -3.69 EPS for the current year.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. This represents a 57.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is owned by company insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.